{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:28:20Z","timestamp":1790742500946,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,11,7]],"date-time":"2015-11-07T00:00:00Z","timestamp":1446854400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12879-015-1261-9","type":"journal-article","created":{"date-parts":[[2015,11,7]],"date-time":"2015-11-07T15:03:50Z","timestamp":1446908630000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection"],"prefix":"10.1186","volume":"15","author":[{"given":"Teresa L.","family":"Kauf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"McKinnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Ralph","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bedolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F.","family":"Riska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Jauregui-Peredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Hoehns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9e-Claude","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Garcia-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K.","family":"Brenneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lodise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,7]]},"reference":[{"key":"1261_CR1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1155\/2004\/383461","volume":"15","author":"AJ Rosner","year":"2004","unstructured":"Rosner AJ, Becker DL, Wong AH, Miller E, Conly JM. The costs and consequences of methicillin-resistant Staphylococcus aureus infection treatments in Canada. Can J Infect Dis Med Microbiol. 2004;15:213\u201320.","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"Suppl 2","key":"1261_CR2","first-page":"ii37","volume":"51","author":"D Nathwani","year":"2003","unstructured":"Nathwani D. Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter? J Antimicrob Chemother. 2003;51 Suppl 2:ii37\u201344.","journal-title":"J Antimicrob Chemother"},{"key":"1261_CR3","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.290.12.1624","volume":"290","author":"SR Tunis","year":"2003","unstructured":"Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290:1624\u201332.","journal-title":"JAMA"},{"key":"1261_CR4","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jclinepi.2008.12.011","volume":"62","author":"KE Thorpe","year":"2009","unstructured":"Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol. 2009;62:464\u201375.","journal-title":"J Clin Epidemiol"},{"key":"1261_CR5","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1086\/420818","volume":"38","author":"RD Arbeit","year":"2004","unstructured":"Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673\u201381.","journal-title":"Clin Infect Dis"},{"key":"1261_CR6","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1086\/497143","volume":"41","author":"DL Stevens","year":"2005","unstructured":"Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41:1373\u2013406.","journal-title":"Clin Infect Dis"},{"key":"1261_CR7","unstructured":"Cubicin (daptomycin for injection) [package insert]. Lexington, MA: Cubist Pharmaceuticals; 2013."},{"key":"1261_CR8","doi-asserted-by":"crossref","unstructured":"Cleeland CS. Brief Pain Inventory (Short Form). Pain Research Group. MD Anderson Center. Houston, TX; 1991. [ http:\/\/www.mdanderson.org\/education-and-research\/departments-programs-and-labs\/departmentsand-divisions\/symptom-research\/symptom-assessment-tools\/brief-pain-inventory.html ].","DOI":"10.1037\/t04175-000"},{"key":"1261_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"The EuroQol Group","year":"1990","unstructured":"The EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199\u2013208.","journal-title":"Health Policy"},{"key":"1261_CR10","unstructured":"Agency for Healthcare Research and Quality. Overview of the Nationwide Inpatient Sample (NIS). 2014. [ http:\/\/www.hcup-us.ahrq.gov\/nisoverview.jsp ]."},{"key":"1261_CR11","unstructured":"Aggregate Hospital Payment-to-cost Ratios for Private Payers, Medicare and Medicaid, 1991 \u20132011. Trendwatch Chartbook. 2014. Table 4.4. [ http:\/\/www.aha.org\/research\/reports\/tw\/chartbook\/2013\/13chartbook-full.pdf ]."},{"key":"1261_CR12","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1592\/phco.27.12.1611","volume":"27","author":"SL Davis","year":"2007","unstructured":"Davis SL, McKinnon PS, Hall LM, Delgado Jr G, Rose W, Wilson RF, et al. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes. Pharmacotherapy. 2007;27:1611\u20138.","journal-title":"Pharmacotherapy"},{"key":"1261_CR13","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1086\/510386","volume":"44","author":"ME Stryjewski","year":"2007","unstructured":"Stryjewski ME, Szczech LA, Benjamin Jr DK, Inrig JK, Kanafani ZA, Engemann JJ, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis. 2007;44:190\u20136.","journal-title":"Clin Infect Dis"},{"key":"1261_CR14","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1592\/phco.23.5.643.32199","volume":"23","author":"W Darko","year":"2003","unstructured":"Darko W, Medicis JJ, Smith A, Guharoy R, Lehmann DE. Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy. 2003;23:643\u201350.","journal-title":"Pharmacotherapy"},{"key":"1261_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1592\/phco.19.4.257.30933","volume":"19","author":"CM Karam","year":"1999","unstructured":"Karam CM, McKinnon PS, Neuhauser MM, Rybak MJ. Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. Pharmacotherapy. 1999;19:257\u201366.","journal-title":"Pharmacotherapy"},{"key":"1261_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2217\/cer.12.9","volume":"1","author":"DP Buesching","year":"2012","unstructured":"Buesching DP, Luce BR, Berger ML. The role of private industry in pragmatic comparative effectiveness trials. J Comp Eff Res. 2012;1:147\u201356.","journal-title":"J Comp Eff Res"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-015-1261-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-015-1261-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-015-1261-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T10:08:04Z","timestamp":1567332484000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-015-1261-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,7]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1261"],"URL":"https:\/\/doi.org\/10.1186\/s12879-015-1261-9","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,7]]},"article-number":"503"}}